Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Robert Burns
HC

Robert Burns

H.C. Wainwright
Wall Street Analyst
★★☆☆☆
#2889
on 13Foresight · ranked by our own returns
36%
Success Rate
-14.1%
Average Return
47 of 130 calls profitable · -164.9% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 36% of Robert Burns's ratings turned a profit when each position was held for 1 year — averaging -14.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.
Robert's Stock Coverage 53 ratings · 2026-11-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
TNGX
Tango Therapeutics
 Oct 29, 2026 BUY Strong Buy
+76.4% avg upside
16 analysts
$68.00
199.24% Upside
 +13.2% ·
BDTX
Black Diamond Therapeutics
 Oct 29, 2026 BUY Strong Buy
+703.4% avg upside
12 analysts
$11.00
518.01% Upside
 +0.0% ·
AVBP
ArriVent BioPharma, Inc.
 Oct 28, 2026 BUY Strong Buy
+89.4% avg upside
15 analysts
$27.00
81.54% Upside
 -18.1% ·
HURA
TuHURA Biosciences
 Oct 27, 2026 BUY Strong Buy
+376.7% avg upside
8 analysts
$10.00
418.18% Upside
 -22.8% ·
ORIC
Oric Pharmaceuticals
 Oct 27, 2026 BUY Strong Buy
+160.3% avg upside
21 analysts
$27.00
192.24% Upside
 -10.6% ·
ELTX
Elicio Therapeutics
 Oct 26, 2026 BUY Buy
+730.6% avg upside
11 analysts
$23.00
1269.00% Upside
 -4.1% ·
PBLS
Parabilis Medicines, Inc.
 Oct 26, 2026 BUY Strong Buy
+47.4% avg upside
7 analysts
$40.00
41.28% Upside
 +12.9% ·
ELVN
Enliven Therapeutics
 Oct 19, 2026 BUY Strong Buy
+40.0% avg upside
18 analysts
$73.00
64.93% Upside
 +22.8% ·
NRIX
Nurix Therapeutics
 Oct 16, 2026 BUY Strong Buy
+22.5% avg upside
28 analysts
$36.00
34.31% Upside
 -36.2% ·
PRLD
Prelude Therapeutics
 Oct 13, 2026 BUY Hold
+179.8% avg upside
7 analysts
$8.00
106.25% Upside
 +6.2% ·
CRBU
Caribou Biosciences
 Oct 08, 2026 HOLD Buy
+1510.4% avg upside
13 analysts
 — -18.8% ·
CGEM
Cullinan Management
 Oct 02, 2026 BUY Strong Buy
+135.1% avg upside
16 analysts
$35.00
132.96% Upside
 -34.4% ·
TLX
Telix Pharmaceuticals Limited Unsponsored ADR
 Sep 30, 2026 BUY Strong Buy
+119.8% avg upside
2 analysts
$20.00
119.76% Upside
 -15.9% ·
BLSM
BlossomHill Therapeutics, Inc.
 Sep 30, 2026 BUY Strong Buy
+157.5% avg upside
5 analysts
$35.00
154.63% Upside
 -20.4% ·
ACET
Adicet Bio
 Sep 29, 2026 BUY Strong Buy
+665.1% avg upside
14 analysts
$34.00
894.19% Upside
 -57.1% ·
COGT
Cogent Biosciences
 Sep 16, 2026 BUY Strong Buy
+24.4% avg upside
26 analysts
$55.00
77.30% Upside
 -11.6% ·
CRDF
Cardiff Oncology
 Sep 15, 2026 BUY Strong Buy
+1092.7% avg upside
18 analysts
$9.00
911.74% Upside
 -46.3% ·
INBX
Inhibrx Biosciences Inc
 Sep 09, 2026 BUY Strong Buy
+271.5% avg upside
6 analysts
$245.00
241.39% Upside
 -22.2% ·
PMVP
PMV Pharmaceuticals
 Sep 08, 2026 BUY Strong Buy
+951.7% avg upside
13 analysts
$5.00
281.65% Upside
 -10.4% ·
RVMD
Revolution Medicines
 Aug 27, 2026 BUY Strong Buy
+8.2% avg upside
36 analysts
$280.00
46.37% Upside
 -21.6% ·
ZYME
Zymeworks
 Aug 26, 2026 BUY Strong Buy
+18.4% avg upside
26 analysts
$55.00
92.23% Upside
 -9.7% ·
RLAY
Relay Therapeutics
 Aug 21, 2026 BUY Strong Buy
+22.4% avg upside
22 analysts
$29.00
58.08% Upside
 -8.1% ·
IMMX
Immix Biopharma
 Aug 10, 2026 BUY Strong Buy
+179.7% avg upside
9 analysts
$25.00
225.58% Upside
 -20.9% ·
NUVB
Nuvation Bio
 Aug 07, 2026 BUY Strong Buy
+178.0% avg upside
18 analysts
$21.00
341.17% Upside
 -38.2% ·
KPTI
Karyopharm Therapeutics
 Jul 31, 2026 HOLD Strong Buy
+2682.1% avg upside
18 analysts
$3.00
353.19% Upside
 · ·
OKUR
OnKure Therapeutics
 Jul 20, 2026 BUY Buy
+743.5% avg upside
13 analysts
$21.00
701.47% Upside
 -27.9% ·
FATE
Fate Therapeutics
 Jul 09, 2026 BUY Buy
+482.8% avg upside
31 analysts
$7.00
236.56% Upside
 -56.9% ·
MOLN
Molecular Partners
 Jul 06, 2026 BUY Buy
+179.3% avg upside
7 analysts
$13.00
263.12% Upside
 -22.8% ·
EXEL
Exelixis
 Jul 02, 2026 BUY Buy
-34.0% avg upside
34 analysts
$56.00
19.20% Downside
 +23.8% ·
ADCT
ADC Therapeutics
 Jun 08, 2026 HOLD Strong Buy
+239.2% avg upside
12 analysts
 — +38.8% ·
RADX
Radiopharm Theranostics Limited Sponsored ADR
 Jun 04, 2026 BUY Strong Buy
+1590.0% avg upside
6 analysts
$16.00
1381.57% Upside
 -82.3% ·
AKTS
Aktis Oncology, Inc.
 Jun 03, 2026 BUY Strong Buy
+104.0% avg upside
12 analysts
$35.00
119.75% Upside
 -17.5% ·
BCAX
Bicara Therapeutics Inc.
 Jun 01, 2026 BUY Strong Buy
+247.1% avg upside
16 analysts
$42.00
360.04% Upside
 -52.8% ·
CATX
Perspective Therapeutics
 Jun 01, 2026 BUY Strong Buy
+759.3% avg upside
24 analysts
$13.00
1030.40% Upside
 -76.5% ·
BOLT
Bolt Biotherapeutics
 May 28, 2026 BUY Buy
+294.6% avg upside
7 analysts
$7.00
6.24% Upside
 +18.1% ·
MGNX
MacroGenics
 May 07, 2026 HOLD Buy
+638.9% avg upside
25 analysts
 — -20.4% ·
BBOT
BridgeBio Oncology Therapeutics
 May 01, 2026 BUY Strong Buy
+714.3% avg upside
11 analysts
$29.00
1006.97% Upside
 -72.0% ·
BNTX
BioNTech SE
 Apr 27, 2026 BUY Strong Buy
+48.9% avg upside
28 analysts
$130.00
47.36% Upside
 -17.0% ·
WHWK
Whitehawk Therapeutics
 Apr 21, 2026 HOLD Buy
+274.2% avg upside
15 analysts
 — -23.1% ·
ALLO
Allogene Therapeutics
 Apr 16, 2026 BUY Strong Buy
+1186.8% avg upside
28 analysts
$11.00
832.23% Upside
 -62.0% ·
REPL
Replimune Group
 Apr 13, 2026 SELL Strong Buy
+40.9% avg upside
14 analysts
 — -1171.8% ·
AUTL
Autolus Therapeutics
 Feb 13, 2026 BUY Strong Buy
+599.0% avg upside
16 analysts
$8.00
426.38% Upside
 -3.2% ·
ATRA
Atara Biotherapeutics
 Aug 19, 2025 HOLD Buy
+125.9% avg upside
18 analysts
 — -16.4% ·
APLM
Apollomics
 Sep 03, 2024 HOLD Strong Buy
-23.8% avg upside
3 analysts
 — -62.9% ·
EFTR
eFFECTOR Therapeutics
 Jul 16, 2024 HOLD Strong Buy
+66249900.0% avg upside
5 analysts
 — · ·
GTBP
GT Biopharma
 May 24, 2024 HOLD Strong Buy
+96.0% avg upside
3 analysts
 — -21.5% ·
CLDI
Calidi Biotherapeutics
 Mar 21, 2024 BUY Strong Buy
+1486.3% avg upside
3 analysts
$20.00
2806.88% Upside
 · ·
ALP
Alpha Compute
 Jan 08, 2024 HOLD Strong Buy
+974.7% avg upside
7 analysts
 — · ·
NGNE
Neurogene
 Mar 21, 2023 HOLD Buy
+79.4% avg upside
24 analysts
 — +269.0% ·
IMA
ImageneBio
 Mar 17, 2023 BUY Strong Buy
+336.6% avg upside
13 analysts
$22.00
436.67% Upside
 -61.8% ·
CTMX
CytomX Therapeutics
 May 10, 2022 BUY Strong Buy
+361.2% avg upside
21 analysts
$11.00
370.03% Upside
 +2.2% ·
SE:ONCO
Oncopeptides AB
 Oct 22, 2021 SELL Hold
2 analysts
 — -205.7% ·
NCNA
Nucana
 Mar 05, 2021 BUY Buy
+1147.5% avg upside
9 analysts
$10.00
890.14% Upside
 · ·
🔒 48 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Robert Burns — Frequently Asked Questions
How accurate are Robert Burns's stock ratings?
Based on the calls 13Foresight could measure, about 36% of Robert's ratings were profitable over a one-year hold, with an average return of -14.1% per rating, or -164.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Robert ranked on 13Foresight?
Robert Burns is currently ranked #2889 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Robert cover?
Robert most recently has ratings on TNGX, BDTX, AVBP, HURA, ORIC, ELTX, PBLS, ELVN, NRIX, PRLD, CRBU, CGEM and 41 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.